{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:42:59Z","timestamp":1777506179248,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","geriatriconcology.net","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.jgo.2016.07.007","type":"journal-article","created":{"date-parts":[[2016,8,3]],"date-time":"2016-08-03T11:04:42Z","timestamp":1470222282000},"page":"375-382","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["New treatment approaches in CLL: Challenges and opportunities in the elderly"],"prefix":"10.1016","volume":"7","author":[{"given":"Barbara","family":"Eichhorst","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentin","family":"Goede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jgo.2016.07.007_bb0005","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2016.07.007_bb0010","series-title":"SEER Cancer Statistics Review, 1975\u20132011","author":"Howlader","year":"2014"},{"issue":"1","key":"10.1016\/j.jgo.2016.07.007_bb0015","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/10428190701724785","article-title":"Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia","volume":"49","author":"Thurmes","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.jgo.2016.07.007_bb0020","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1532-5415.1968.tb02103.x","article-title":"Cumulative illness rating scale","volume":"16","author":"Linn","year":"1968","journal-title":"J Am Geriatr Soc"},{"issue":"10","key":"10.1016\/j.jgo.2016.07.007_bb0025","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3324\/haematol.2014.107326","article-title":"Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model","volume":"99","author":"Baumann","year":"2014","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.jgo.2016.07.007_bb0030","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00280-002-0443-5","article-title":"Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study","volume":"50","author":"Martell","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jgo.2016.07.007_bb0035","article-title":"Interactions between comorbidity and treatment of chronic lymphocytic leukemia: trial results of the German CLL Study Group","volume":"28","author":"Goede","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.jgo.2016.07.007_bb0040","first-page":"1","article-title":"Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: results of the CLL9 trial of the German CLL study group","volume":"13","author":"Goede","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.jgo.2016.07.007_bb0045","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jgo.2015.08.003","article-title":"How I treat chronic lymphocytic leukemia in older patients","volume":"6","author":"Heraly","year":"2015","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.jgo.2016.07.007_bb0050","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia: a randomised, open-label, phase III trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jgo.2016.07.007_bb0055","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jgo.2016.07.007_bb0060","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jgo.2016.07.007_bb0065","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1002\/cncr.22662","article-title":"Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia","volume":"109","author":"Shanafelt","year":"2007","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.jgo.2016.07.007_bb0070","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2016.07.007_bb0075","article-title":"Randomised dose de-escalation study of oral fludarabine, \u00b1oral cyclophosphamide and intravenous rituximab as first-line therapy of fit patients with chronic lymphocytic leukaemia (CLL) aged \u226565years: final analysis of response and toxicity","volume":"124","author":"Mulligan","year":"2014","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.jgo.2016.07.007_bb0080","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.4670.4670","article-title":"Low-dose FCR is a safe and effective treatment option for elderly\/comorbid patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma. Updated results of project Q-Lite by Czech CLL Study Group","volume":"124","author":"Smolej","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2016.07.007_bb0085","first-page":"1","article-title":"Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia","volume":"28","author":"Dartigeas","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.jgo.2016.07.007_bb0090","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3324\/haematol.2012.070755","article-title":"Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia","volume":"98","author":"Bouvet","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.jgo.2016.07.007_bb0095","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1182\/blood.V126.23.4156.4156","article-title":"Prognostic impact and risk factors of reducing prescribed doses of fludarabine, cyclophosphamide and rituximab (FCR) during frontline treatment of chronic lymphocytic leukemia (CLL)","volume":"126","author":"Kovacs","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2016.07.007_bb0100","volume":"124","author":"Eichhorst","year":"2014","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.jgo.2016.07.007_bb0105","article-title":"Rituximab in combination with bendamustine or chlorambucil for the treatment of chronic lymphocytic leukaemia: Primary results from the randomised phase IIIb MABLE study","volume":"56","author":"Michallet","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jgo.2016.07.007_bb0110","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.24430","article-title":"A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed","author":"Flinn","year":"2016","journal-title":"CLL. Am J Hematol"},{"key":"10.1016\/j.jgo.2016.07.007_bb0115","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3109\/10428194.2014.933217","article-title":"Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma","volume":"56","author":"Ujjani","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jgo.2016.07.007_bb0120","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1182\/blood.V126.23.493.493","article-title":"Safety and efficacy of obinutuzumab plus bendamustine in previously untreated patients with chronic lymphocytic leukemia: subgroup analysis of the green study","volume":"126","author":"Stilgenbauer","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jgo.2016.07.007_bb0125","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2016.07.007_bb0130","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/leu.2015.14","article-title":"Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study","volume":"29","author":"Goede","year":"2015","journal-title":"Leukemia"},{"issue":"9980","key":"10.1016\/j.jgo.2016.07.007_bb0135","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","article-title":"Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial","volume":"385","author":"Hillmen","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jgo.2016.07.007_bb0140","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","article-title":"Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2 trial","volume":"15","author":"O'Brien","year":"2014","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.jgo.2016.07.007_bb0145","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2016.07.007_bb0150","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.jgo.2016.07.007_bb0155","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1182\/blood-2015-03-630947","article-title":"A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia","volume":"126","author":"O'Brien","year":"2015","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jgo.2016.07.007_bb0160","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jgo.2016.07.007_bb0165","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood-2013-04-495341","article-title":"Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia","volume":"122","author":"Strati","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2016.07.007_bb0170","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"6","author":"Roberts","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2016.07.007_bb0175","volume":"126","author":"Fischer","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jgo.2016.07.007_bb0180","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3109\/10428194.2014.963077","article-title":"Past, present and future role of chlorambucil in the treatment of chronic lymphocytic leukemia","volume":"56","author":"Goede","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.jgo.2016.07.007_bb0185","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","article-title":"Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial","volume":"30","author":"Bottcher","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406816300960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406816300960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T21:21:28Z","timestamp":1656969688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406816300960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S1879406816300960"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2016.07.007","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New treatment approaches in CLL: Challenges and opportunities in the elderly","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2016.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}